Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.
We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method. Twenty patients optimized on conventional CHF therapy were treated with spironolactone, and brachial artery flow- mediated dilation was measured at baseline and at 4 and 8 weeks. Spironolactone improved endothelial function at 4 weeks, and sustained the improvement at 8 weeks, in patients with CHF on conventional medical therapy, presumably due to reversal of aldosterone impairment of endothelial nitric oxide activity.
Abiose
Ademola K
AK
Division of Cardiology, Creighton University School of Medicine, Omaha, Nebraska, USA. ademola@pol.net
Mansoor
George A
GA
Barry
MaryBeth
M
Soucier
Richard
R
Nair
Chandra K
CK
Hager
David
D
D000368:Aged; D000369:Aged, 80 and over; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000502:physiology; D003326:Coronary Circulation / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D013148:Spironolactone / Q000494:pharmacology*; D014463:Ultrasonography; D014664:Vasodilation / Q000502:physiology
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone